Lopinavir/Ritonavir-based Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-infected Naive Children-Reference-Cited by-同舟云学术

Lopinavir/Ritonavir-based Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-infected Naive Children

Published:2011-08 Issue:8 Volume:30 Page:684-688
ISSN:0891-3668
Container-title:Pediatric Infectious Disease Journal
language:en
Short-container-title:

Author:

Frange Pierre,Briand Nelly,Avettand-fenoel Véronique,Veber Florence,Moshous Despina,Mahlaoui Nizar,Rouzioux Christine,Blanche Stéphane,Chaix Marie-Laure

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Microbiology (medical),Pediatrics, Perinatology, and Child Health

Reference37 articles.

1. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.;Ortiz;AIDS,2008

2. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.;Eron;Lancet,2006

3. Class-sparing regimens for initial treatment of HIV-1 infection.;Riddler;N Engl J Med,2008

4. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.;Soulie;AIDS,2009

5. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.;Saez-Llorens;Pediatr Infect Dis J,2003

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV: a systematic review and meta-analysis;The Lancet Child & Adolescent Health;2022-10

2. Growth in HIV-1-exposed but uninfected infants treated with lopinavir–ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial;The Lancet HIV;2019-05

3. Infección del niño por el virus de la inmunodeficiencia humana de tipo 1;EMC - Pediatría;2018-03

4. Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014;PLOS ONE;2017-03-28

5. Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d’Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort;Journal of the International AIDS Society;2017